Why Choose Next Generation Flow™?
Accelerate your research with BD’s Next Generation Flow™ Solution—an ultrasensitive, standardized approach that enables precise analysis of millions of cells (up to 10⁻⁶). Designed to support minimal residual disease (MRD) and primary immunodeficiency research, this integrated solution empowers you to move from sample to insight.
End-to-End Standardization
Ensure consistency and reliability with:
- EuroFlow™-approved protocols.
- Ready-to-use panels validated by multicenter clinical research groups.1,2
- Automated analysis and reporting powered by expert-developed databases.1, 2, 3
-
Accelerated time to insight
Get results within hours of sample receipt—minimizing time spent on validation and maximizing time for innovation.4,5 -
Streamlined workflow efficiency
Simplify your process with intuitive protocols, pre-validated panels, and automated tools that reduce manual effort and error. -
Unmatched analytical power
Perform comprehensive immunophenotyping, analyze complex cell populations, and compare results against reference ranges with confidence. -
Global expert support
BD’s technical specialists are here to help you implement and scale these solutions worldwide.
BD Cytognos™ Multiple Myeloma MRD
Plasma cell panel endorsed by the IMWG as the gold standard for multicolor flow cytometry MRD studies including research studies of samples obtained post-anti-CD38 therapy.
BD Cytognos™ Primary Immunodeficiency Orientation Tube
Standardized panel for immune profiling in peripheral blood supported by age-matched reference ranges enables detection of ESID-defined lymphocyte subpopulations.
BD Cytognos™B-Cell Precursor Acute Lymphoblastic Leukemia MRD
Panel for standardized detection of normal and aberrant B-cell precursors including research studies of samples obtained post-CD19-targeted therapies.
Watch Our Next Generation Flow™ webinars
“Next Generation Flow™ Technology in Multiple Myeloma Clinical Trials”
- Dr. Bruno Paiva, PhD
"Next Generation Flow™ for Earlier Detection of Primary Immunodeficiency: Impact of late diagnosis in adult patients”
- Dr. Fernando Solano, MD, PhD, and Dr. Nahir Moreno, MD
“Comprehensive Analysis using Next Generation Flow™ in Multiple Myeloma MRD”
- Dr. Juan Flores-Montero, MD, PhD
“TBNK vs. Next Generation Flow Primary Immunodeficiency Orientation Tube testing for the screening of inborn errors of immunity”
- Professor Martín Perez-Andrés, PhD
References
- Kalina T, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26, 1986-2010. doi: 10.1038/leu.2012.122
- Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129(3):347-357. Doi:10.1182/blood-2016-07-726307
- van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996-4009. Doi:10.1182/blood-2015-03-580027
- Flores-Montero J, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103. Doi:10.1038/leu.2017.29
- van der Burg M, et al. The EuroFlow PID Orientation Tube for flow cytometric diagnostic screening of Primary Immunodeficiencies of the lymphoid system. Front Immunol. 2019:10:246. Doi:10.3389/fimmu.2019.00246.
- Verbeek M, et al. Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: a EuroFlow study. Cytometry B Clin Cytom. 2024 Jul;106(4):252-263. doi: 10.1002/cyto.b.22143.
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. Doi:10.1016/S1470-2045(16)30206-6.
- Selliah N, et al. Multiple Myeloma EuroFlow assay validation for Clinical Trials. Poster presented at: ICCS 2019; Atlanta, Georgia, US.
- Van Dongen JJM, van der Burg M, Kalina T, et al. EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System. Front Immunol. 2019;10:1271. Published 2019 Jun 13. Doi:10.3389/fimmu.2019.01271
- Verbeek M, et al. Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study. HemaSphere. 2025;9:e70125. doi: 10.1002/hem3.70125
Request a Consultation
*Required fields